Aporphine and oxoaporphine compounds and pharmaceutical use thereof
申请人:Su Mingjai
公开号:US20060211723A1
公开(公告)日:2006-09-21
The invention provides aporphine and oxoaporphine compounds that may be used to manufacture a medicaments for preventing or treating vascular dysfunctions that may result in ischemic and metabolic diseases or preventing complications associated with these diseases in human and mammal. The ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc. The metabolic disease may include diabetes-induced vascular diseases, such as hypertension, atherosclerosis, peripheral artery or venous thrombosis, retinopathy and nephropathy. Methods for treating ischemic and metabolic diseases or preventing complications are also disclosed.
A novel synthesis of aporphine alkaloids via o-quinol acetates.
作者:OSAMU HOSHINO、MINORU OHTANI、BUNSUKE UMEZAWA
DOI:10.1248/cpb.26.3920
日期:——
Lead tetraacetate oxidation of 1-(3', 4'-dimethoxy- or 3', 4'-methylenedioxy-benzyl)-6-hydroxy-7-methoxy-2-methyl-1, 2, 3, 4-tetrahydroisoquinoline (1a or 1b) in CH2Cl2 was found to give quantitatively a diastereomeric mixture (1 : 1) of an o-quinol acetate (2a or 2b), treatment of which with Ac2O-conc. H2SO4 at room temperature led to (±)-O-acetyl-predicentrine (5a) or -isodomesticine (5b). Furthermore, hydrolysis of 5a or 5b with 1.7% KOH-MeOH afforded (±)-predicentrine (6a) or (±)-isodomesticine (6b).